LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Genomic Sequencing Illuminates Recent Shigellosis Outbreaks

By LabMedica International staff writers
Posted on 12 Jan 2017
Image: The Wizard SV Genomic DNA purification system (Photo courtesy of Promega).
Image: The Wizard SV Genomic DNA purification system (Photo courtesy of Promega).
Shigellosis is an acute gastrointestinal infection caused by bacteria belonging to the genus Shigella. Shigellosis is the third most common enteric bacterial infection in the USA with 500,000 infections, 6,000 hospitalizations, and 70 deaths each year.

There are four Shigella species that cause shigellosis: Shigella dysenteriae, considered to be the most virulent species due to its ability to produce a potent cytotoxin called Shiga toxin, while S. flexneri, S. boydii, and S. sonnei generally do not produce Shiga toxin and, therefore, cause mild forms of shigellosis.

Scientists at the California Department of Public Health (Richmond, CA, USA) and their colleagues identified 68 Shigella sonnei human isolates from California (CA); 57 outbreak-related isolates from 2014 to 2015 and 11 archival isolates from 1980 to 2008, which were serotyped by standard methods. Polymerase chain reaction (PCR) detection of the stx1 and stx2 genes and Vero cell neutralization assay for confirmation of Shiga toxin production were performed.

DNA was extracted with a Wizard Genomic DNA kit (Promega, Madison, WI, USA). Sequencing libraries were constructed using the Nextera XT (Illumina Inc, San Diego, CA, USA) library preparation kit. Sequencing was performed using 2 × 300-bp sequencing chemistry on an Illumina MiSeq sequencer. High-quality single nucleotide polymorphism (hqSNP)-based phylogeny was used to determine genetic relationships between the local California (CA) S. sonnei populations and their connection to global S. sonnei strains.

The team found two clusters in these outbreaks: one that primarily struck San Diego and the San Joaquin Valley and one more localized to the San Francisco Bay Area. The San Diego/San Joaquin strain has been in California since at least 2008. However, some of the isolates had been infected with a bacteriophage (a virus that attacks bacteria) that carried a Shiga toxin (stx) gene found in the more virulent S. flexneri and S. dysenteriae. By contrast, the strain that hit San Francisco lacked stx but contained genes that gave it resistance to the broad-spectrum fluoroquinolone class of antibiotics. The fluoroquinolone-resistance genes were similar to ones found in strains from Southeast Asia.

James P Watt, MD, MPH, the Chief of Division of Communicable Disease Control, said, “Shigella sonnei bacteria normally cause a less severe disease and are not known to produce Shiga toxin. The toxin gene was most likely acquired by Shigella sonnei via genetic exchanges with Escherichia coli and other Shigella species. Discovering a functional toxin gene was concerning in this large outbreak. Finding this gene raises concerns that illness due to Shigella sonnei could become more severe in the future.” The study was published on December 21, 2016, in the journal mSphere.

Related Links
California Department of Public Health
Promega
Illumina

Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hematology System
Medonic M16C
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more